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Abstract 
Background. Epileptic encephalopathies represent the most severe epilepsies, with onset in 
infancy and childhood and seizures continuing in adulthood in most cases. New genetic 
causes are being identified at a rapid rate. Treatment is challenging and the overall outcome 
remains poor. Available targeted treatments, based on the precision medicine approach, are 
currently few. 
Objective. To provide an overview of the treatment of epileptic encephalopathies with known 
genetic determinants, including established treatment, anecdotal reports of specific treatment, 
and potential tailored precision medicine strategies. 
Method.	Genes known to be associated to epileptic encephalopathy were selected. Genes 
where the association was uncertain or with no reports of details on treatment, were not 
included. Although some of the genes included are associated with multiple epilepsy 
phenotypes or other organ involvement, we have mainly focused on the epileptic 
encephalopathies and their antiepileptic treatments.  
Results. Most epileptic encephalopathies show genotypic and phenotypic heterogeneity. The 
treatment of seizures is difficult in most cases. The available evidence may provide some 
guidance for treatment: for example, ACTH seems to be effective in controlling infantile 
spams in a number of genetic epileptic encephalopathies. There are potentially effective 
tailored precision medicine strategies available for some of the encephalopathies, and 
therapies with currently unexplained effectiveness in others. 
Conclusions. Understanding the effect of the mutation is crucial for targeted treatment. There 
is a broad range of disease mechanisms underlying epileptic encephalopathies, and this 
makes the application of targeted treatments challenging. However, there is evidence that 
tailored treatment could significantly improve epilepsy treatment and prognosis. 
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Introduction 
Severe epilepsies starting in infancy and childhood represent a significant proportion of 
intractable epilepsies characterised by frequent epileptic seizures and developmental delay, 
arrest, or regression. Co-morbidities are common, and include autism spectrum disorder, and 
behavioural and movement disorders. The overall outcome, including epilepsy, co-
morbidities and quality of life, is often poor. These conditions, in which the epileptiform 
abnormalities are thought to significantly contribute to the overall functional brain 
disturbance, are referred to as epileptic encephalopathies [1,2]. However, in most patients 
with severe epilepsy and in most genetic epilepsies, distinguishing between the contributions 
of the epilepsy activity (including seizures and interictal epileptiform activity) and of the 
underlying disease is difficult [3]. Nevertheless the term ‘epileptic encephalopathies’ is 
widely accepted by the epilepsy community and encompasses a broad range of clinical 
syndromes characterized by severe phenotypes. Whilst these conditions start in infancy and 
childhood, it is important to note that many affected individuals live on into adulthood, in 
which age group the concept of ‘epileptic encephalopathy’ is generally less well recognised. 
The longer term outcomes for seizure control are not well documented, and most available 
data come from studies in children, upon which we largely rely.  
A prospective population-based study estimated an ascertainment-adjusted incidence of 
epilepsy of 70.1 (95% CI [56.3, 88.5])/100,000 children less than two years of age/year (with 
76% completeness of ascertainment). Epileptic encephalopathy was the electroclinical 
syndrome in 22 of 57 infants (39%), but the overall incidence of epileptic encephalopathies 
was probably underestimated because many disorders in children were not classifiable 
despite poor seizure outcomes and developmental impairment [4]. There are no data available 
in adults.   
Epileptic encephalopathies comprise many age-related epilepsy syndromes characterised by 
specific seizure types, EEG, and neurological features, sometimes with additional extra-
neurological aspects. The era of genome-wide screening technologies has allowed the 
identification of more and more genes which when mutated cause epileptic encephalopathies, 
leading to delineation of more or less distinctive electroclinical features and comorbidities for 
specific genetic encephalopathies. However, there remains a significant degree of genetic and 
phenotypic pleiotropy. Furthermore, although a number of recent studies have identified 
additional epileptic encephalopathy genes in large cohorts through whole exome  or targeted 
sequencing [5-10], currently a genetic diagnosis in the clinic can be made in ~10-15% of 
tested  patients [11].  
The treatment of epileptic encephalopathies is often challenging	as epilepsy is severe and 
drug-resistant in most cases. Various combinations of antiepileptic drugs and vitamin 
supplements are often used. Alternative methods of treatment, such as vagal nerve stimulator 
therapy and the ketogenic diet, offer relief in a number of patients. Surgical treatments, 
including corpus callosotomy, multiple sub-pial transections, hemispherectomy, or focal 
epilepsy surgery, could be considered in selected patients. Balancing effectiveness and 
tolerability is not always easy [12]. 
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‘Precision medicine’ is an approach for disease treatment and prevention for each person 
based on individual variability in genes, environment, and lifestyle [13]. This approach, 
incorporating the identification of an underlying genetic aetiology to promote personalised 
therapeutic choice, or to drive re-purposing of drugs, builds upon thoughtful clinical practice 
that has been applied for years. The ‘precision medicine’ paradigm has been implemented 
with discovery of a genetic aetiology in more and more epilepsy cases, and with the wider 
availability of the necessary genetic technologies [14-16]. In epilepsy, if a specific gene 
mutation causes a functional alteration of physiological systems involved in the control of 
brain excitability, a rational treatment strategy might ideally aim to reverse or circumvent the 
dysfunction. The current targeted treatment approach in precision medicine requires the 
identification of the underlying causative genetic alteration, determination of the functional 
alteration of the physiological system caused by the genetic mutation, and evaluation of the 
effect of treatment putatively intended and able to reverse or inhibit the functional alteration. 
The aim of targeted treatment is to improve not only seizure control, but also developmental 
outcome and associated co-morbidities, by directly addressing the mechanisms that produce 
the widespread effects of the disorder, which might be more extensive than epilepsy and 
cognitive dysfunction alone. However, genetic and phenotypic heterogeneity often limit or 
complicate the targeted approach, which may in fact not always prove successful. This might 
be due to a number of reasons, including the fact that no causal variant acts in isolation, but 
does so in the context of the rest of the genome and its variation; the fact that finding the 
genetic aetiology does not necessarily imply that appropriate targeted treatment is available; 
and because of compensatory and adaptive changes that may become difficult to reverse with 
treatment of the perceived original defect. Currently, drug therapies targeted to the underlying 
genetic cause are available for only a minority of genetic epilepsies[17,18]. For the remaining 
patients, treatment options are based on symptomatic strategies (e.g., antiepileptic drugs), 
which in general are not believed to address the underlying systemic functional alteration 
caused by the genetic mutation.	Appropriate treatment strategies are required for children but 
also adults, as epileptic encephalopathies are increasingly recognised in adulthood, and many 
children with epileptic encephalopathies survive to adulthood. 
Here we present an overview of the treatment of epileptic encephalopathies with known 
genetic determinants, including established treatment, anecdotal reports of specific treatment, 
and potential tailored precision medicine strategies. Genes were selected through a systematic 
review of those reported in the recent review by McTague et al. [2]; present in the 104 
Epilepsy Gene Panel of the Glasgow Epilepsy service 
(http://www.nhsggc.org.uk/media/239338/epilepsy-service-proforma-pre-18-revision-2-june-
2016.pdf); or other genes known to be associated to epileptic encephalopathy. Genes where 
the association was uncertain, or with no report of details on treatment, were not included. 
We searched the PubMed database using a combination of terms, including each selected 
gene and “epilepsy” or “epileptic encephalopathy”. We limited search to papers written in 
English. We imposed no limitations on publication date. In many papers, response to 
treatment was described in qualitative terms, which we report without any interpolation. 
Although some of the genes included in this review are associated with multiple epilepsy 
phenotypes or other organ involvement, we have mainly focused on the epileptic 
encephalopathies and the related antiepileptic treatment. It must be appreciated that almost all 
reports are anecdotal: formal treatment trials for most epileptic encephalopathies will need 
novel design. 
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AARS-related epileptic encephalopathy  
The AARS gene encodes alanyl-tRNA synthetase which catalyzes the amino-acylation of 
tRNAAla with alanine in a reaction dependent on ATP. Two siblings and an unrelated child 
were recently reported, with a similar severe neurologic disorder characterized by congenital 
microcephaly and vertical talus, failure to thrive in infancy, spasticity, and refractory 
myoclonic epilepsy with onset between 3 and 6 months. Additional clinical features included 
blepharospasm, orobuccal dyskinesia, dystonia, chorea, and loss of peripheral deep tendon 
reflexes, consistent with a peripheral neuropathy. Their brain MRI showed progressive 
diffuse cerebral atrophy and hypomyelination. This form of early infantile epileptic 
encephalopathy was associated with compound heterozygous (in the two siblings) or 
homozygous (in the unrelated child) missense mutations in the AARS gene. In vitro studies 
showed that the two identified mutations resulted in a significant reduction of AARS 
function. All three cases had ongoing myoclonic and tonic-clonic seizures, despite multiple 
antiepileptic drugs, including levetiracetam, lamotrigine, topiramate, oxcarbazepine, 
phenobarbital, lacosamide, clonazepam, and zonisamide [19]. 
 
ADSL-related epileptic encephalopathy  
Adenylosuccinase (ADSL) is an enzyme involved in two pathways of purine nucleotide 
metabolism [20].	ADSL deficiency is an autosomal recessive inborn error of metabolism 
caused by an enzymatic defect in de novo purine synthesis pathway, leading to the 
accumulation of toxic intermediates, including succinyladenosine (S-Ado) and 
succinylaminoimidazole carboxamide riboside (SAICAr) in body fluids. There are three 
major phenotypic forms of the disorder that correlate with different values of the S-
Ado/SAICAr concentration ratios in the cerebrospinal fluid [21]. Clinical features include 
refractory seizures with variable degrees of hypotonia, global developmental delay, autistic 
traits and progressive brain atrophy [22]. The severity of the clinical symptoms tends to 
correlate inversely with residual enzyme activity. The wide diversity of clinical presentations 
of ADSL deficiency renders systematic screening for the defect mandatory in all patients 
presenting with unexplained intractable neonatal convulsions, severe infantile epilepsy, 
marked or mild psychomotor retardation, hypotonia, microcephaly, autistic features, and 
neurological disease without clear etiology. Diagnosis is based on the presence in urine and 
cerebrospinal fluid of the succinyl purines, S-Ado and SAICA-riboside, both normally nearly 
undetectable. Treatment with oral supplements of adenine and allopurinol or D-ribose and 
uridine have not been associated with significant clinical or biochemical improvement, except 
for some acceleration of growth [23,24]. The prognosis is variable, depending on the severity 
of the phenotype [24]. 
 
ALDH7A1-related epileptic encephalopathy  
The ALDH7A1 gene encodes antiquitin, an aldehyde dehydrogenase	in the pipecolic acid 
pathway of lysine catabolism [25]. Pyridoxine (vitamin B6)-dependent epilepsy is caused by 
bi-allelic mutations in the ALDH7A1 gene. Deficiency of antiquitin causes seizures because 
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accumulating Δ1-piperideine-6-carboxylate (P6C) condenses with pyridoxal 5'-phosphate 
(PLP) and inactivates this enzyme cofactor, which is essential for normal metabolism of 
neurotransmitters. Pyridoxine-dependent epilepsy is characterized by a combination of 
various seizure types, usually occurs in the first hours of life and is resistant to standard 
anticonvulsants, responding only to administration of pyridoxine hydrochloride. The 
dependence is permanent, and the interruption of daily pyridoxine supplementation leads to 
the recurrence of seizures. ALDH7A1 mutation analysis could also be used for prenatal 
diagnosis of pyridoxine-dependent epilepsy. Seizures are often fully controlled by treatment 
with pyridoxine [25]. 
 
ALG13-related epileptic encephalopathy  
ALG13 is located on the X-chromosome and encodes the protein ALG13 which forms the 
UDP-GlcNAc transferase with ALG14 and catalyzes a key step in endoplasmic reticulum N-
linked glycosylation [26]. Seven cases of early infantile epileptic encephalopathy with 
intractable epilepsy, including West syndrome and Lennox-Gastaut syndrome, due to ALG13 
mutations, are reported in the literature [5,27-31]. Some evidence of control of infantile 
spasms is reported with adrenocorticotropic hormone (ACTH) and/or topiramate treatment 
[5,28,31] and ketogenic diet improved seizure control in one case [29]. 
 
ARHGEF9-related epileptic encephalopathy  
The ARHGEF9 gene encodes collybistin, a brain-specific guanine nucleotide exchange factor 
(GEF), belonging to a family of Rho-like GTPases that act as molecular switches by cycling 
from the active GTP-bound state to the inactive GDP-bound state. Collybistin has a pivotal 
role in the formation of postsynaptic glycine and inhibitory gamma-aminobutyric acid 
receptor clusters [32]. A patient with hyperekplexia and early infantile epileptic 
encephalopathy was found to have an ARHGEF9 missense mutation [33]. Lesca et al.[34] 
described a de novo Xq11.11 microdeletion including ARHGEF9 in a patient with severe 
mental retardation, focal epilepsy, tall stature, macrocephaly, and dysmorphism; treatment 
with oxcarbazepine and levetiracetam led to a complete cessation of seizures. Shimojima et 
al. [32] identified a loss-of-function mutation in the ARHGEF9 gene in a patient with early-
onset epileptic encephalopathy and right frontal polymicrogyria; epilepsy was reported as 
drug-resistant. 
 
ARX-related epileptic encephalopathy  
The aristaless-related homeobox gene ARX is a developmentally-regulated homeobox 
transcription factor, located in the human chromosome Xp22 region. It is expressed in the 
developing hypothalamus, thalamus, basal ganglia and cerebral cortex, modulates 
development of interneurons in the fetal brain, and regulates ventricular zone proliferation 
[35]. ARX comprises five exons encoding a protein of 562 aminoacids, including a paired-
class homeodomain and four repeats of 7–16 alanine residues called “polyalanine tracts” 
[36]. In healthy individuals, the maximum length of alanine repeats is twenty [37]. Mutation 
of the second polyalanine tract with expansion by eight more alanine residues, which is the 
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most common mutation in ARX, results in different phenotypes, including West syndrome or 
infantile spasms in males [38,39]. An expansion of seven alanine residues in the first 
polyalanine tract causes West syndrome that is more severe than that caused by the second 
polyalanine tract expansion mutation [38,40,41]: for example, Guerrini et al.[41] described an 
infantile epileptic-dyskinetic encephalopathy, with recurrent life-threatening status dystonicus 
associated with mutation in the first polyalanine tract. An expansion of eleven alanine 
residues in the first polyalanine tract was associated with Early Infantile Epileptic 
Encephalopathy with Suppression-Burst Pattern (Ohtahara Syndrome) [42]. Correlation 
between the length of the repeat and the severity of the clinical phenotype has emerged. Other 
ARX variants have been more recently reported with severe forms of early-onset epileptic 
encephalopathies in males [43-45]. The same phenotype has been also described in females, 
probably due to skewing of X-chromosome inactivation leading to ARX haploinsufficiency 
[46,47]. There is no evidence for specific treatment, with severe drug-resistant epilepsy 
reported in all cases with epilepsy encephalopathy. 
 
BRAT1-related epileptic encephalopathy  
The BRAT1 gene encodes a protein that interacts with the tumor suppressor gene BRCA1 at 
its C terminus and binds to ATM1, considered a master controller of the cell-cycle signaling 
pathways required for cellular responses to DNA damage. BRAT1 may also be involved in 
cell growth and apoptosis [48]. BRAT1 mutations have been associated with particularly 
severe, rapidly progressive, intractable epileptic encephalopathy (including Ohtahara 
syndrome) with age of presentation at birth or shortly thereafter; this phenotype is known as 
rigidity and multifocal seizure syndrome, lethal-neonatal (RMFSL), and has autosomal 
recessive inheritance [48-52]. More recently, milder phenotypes have emerged, with later-
onset epilepsy and survival past infancy [53-55]. In most reported cases, epilepsy was 
refractory to antiepileptic drug treatment or high-dose pyridoxine. In two cases with Ohtahara 
syndrome, zonisamide was effective for tonic-clonic seizures and apneic episodes, but did not 
help control myoclonic seizures; in one of these cases, phenytoin seemed to worsen seizure 
control [51]. In cases with the milder phenotype, clinical and EEG improvement is described 
with levetiracetam [55] or valproate treatment [53]; however, in one case seizures worsened 
with levetiracetam treatment [53]. 
 
CACNA1A-related epileptic encephalopathy  
The CACNA1A gene encodes the transmembrane pore-forming alpha-1A subunit of the P/Q-
type or CaV2.1 voltage-gated calcium channel, acting as an ion pore and a voltage sensor 
[56]. CACNA1A-related epileptic encephalopathies include epilepsy of infancy with 
migrating focal seizures, Lennox-Gastaut syndrome and infantile spasms [5,57-60]. Auvin et 
al. [57] reported a case with a de novo 0.7Mb deletion in 19p13.13 including CACNA1A 
associated with mental retardation and epilepsy with infantile spasms: seizure were initially 
controlled with vigabatrin and  the patient remained seizure-free even after vigabatrin 
withdrawal. Damaj et al.[58] reported three unrelated families with epileptic encephalopathy 
and mild cerebellar symptoms: full seizure control was achieved on a combination of 
valproate, topiramate and levetiracetam, in one case; in another, seizures were partially 
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responsive to a combination of valproate and levetiracetam; intermittent acute cerebellar 
symptoms responded to continuous treatment with acetazolamide. 
 
CACNA2D2-related epileptic encephalopathy  
The CACNA2D2 gene encodes the alpha-2-delta-2 auxiliary subunit of high voltage-gated 
calcium channels. High voltage-gated calcium channels are heteromultimeric protein 
complexes composed of the main channel forming alpha1 subunit, which carries calcium 
influx across the plasma membrane, and the auxiliary subunits beta, gamma, and alpha-2-
delta-2. Auxiliary subunits modulate calcium current and channel activation and inactivation 
kinetics, and may be involved in proper assembly and membrane localization of the channels 
[61]. Only four cases with early-onset epileptic encephalopathy and CACNA2D2 mutations 
have been reported so far: three siblings with early infantile epileptic encephalopathies [61], 
and one patient, offspring to consanguineous parents, with early infantile epileptic 
encephalopathy, dyskinesia, cerebellar atrophy and dysmorphic features [62]. Seizures are 
described as refractory to treatment in the siblings [61], whilst improvement of absence 
seizures with ethosuximide is reported in the case described by Pippucci et al. [62].  
 
CASK-related epileptic encephalopathy  
The CASK gene at Xp11.4 encodes a calcium/calmodulin-dependent serine protein kinase 
that is a member of the membrane-associated guanylate kinase (MAGUK) protein family 
[63]. CASK is involved in synapse formation at both presynaptic and postsynaptic junctions; 
in addition, CASK enters the nucleus and regulates expression of genes involved in cortical 
development [64]. Heterozygous loss of function mutations of CASK in females cause 
epilepsy, severe intellectual disability, and microcephaly with pontine and cerebellar 
hypoplasia. Associated syndromes include epileptic encephalopathies (e.g., West syndrome 
and Lennox-Gastaut syndrome), with drug-resistant epilepsy [65,66]. Male patients present a 
broad phenotypic spectrum ranging from mild (X-linked intellectual disability with or 
without nystagmus) to severe (with early-infantile epileptic encephalopathy and intractable 
seizures; Ohtahara syndrome, West syndrome, or early myoclonic epilepsy), cerebellar 
hypoplasia, and multiple congenital anomalies [65,67-71].  
 
CDKL5-related epileptic encephalopathy  
The CDKL5 gene encodes cyclin-dependent kinase-like 5 and its mutations can cause early-
onset epileptic encephalopathy, including West syndrome, Lennox-Gastaut syndrome or the 
‘early-onset seizure variant of Rett syndrome’ [72-75]. CDKL5 is located on the X 
chromosome (Xp22.13), and therefore genetic traits of CDKL5 alterations have been 
considered to be X-linked dominant [76]. CDKL5 mutations have mainly been reported in 
female patients with an early infantile epileptic encephalopathy phenotype including infantile 
spasms, severe intellectual disability, and ‘Rett-like’ features with absent or limited speech, 
stereotypic hand movements, and deceleration of head growth [77,78]. A distinctive 
electroclinical seizure type with hypermotor-tonic-spasms sequence has been described in 
females with CDKL5-related encephalopathy [79]. The condition seems to be less common, 
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but with a more severe phenotype, in male patients [76,78,80].	The milder clinical spectrum 
of CDKL5 mutations in female patients is hypothesized to be due to variable X-chromosome 
inactivation [81]. In most cases the epilepsy is described as refractory to conventional 
antiepileptic and corticosteroid treatment [73]. Three cases with CDKL5-related epileptic 
encephalopathy had improvement of seizure control following implantation of a vagus nerve 
stimulator [74,82]. 
 
CHD2-related epileptic encephalopathy 
The gene CHD2 encodes chromodomain helicase DNA-binding protein 2, involved in 
transcriptional regulation and chromatin remodelling. CHD2 mutations cause childhood-
onset epileptic encephalopathies, including epilepsy with myoclonic-atonic seizures, fever-
sensitive myoclonic encephalopathy, Lennox-Gastaut syndrome and myoclonic 
encephalopathy with clinical photosensitivity [5,7,83-86]. Most cases had drug-resistant 
epilepsy [86]. However one case with fever-sensitive myoclonic epileptic encephalopathy 
became seizure-free after the introduction of clobazam [84]; and	one case with myoclonic-
atonic seizures was initially treated with valproate with a slight reduction in seizure 
frequency; lamotrigine and clobazam were subsequently added, and he remained seizure-free 
for four years, therefore antiepileptic drugs were gradually withdrawn and six months later he 
had seizure recurrence and valproate was restarted with only two further seizures, both 
photoinduced [87]. 
 
CLCN4-related epileptic encephalopathy 
The X-chromosomal gene CLCN4 encodes the voltage-dependent 2Cl−/H+-exchanger ClC-4 
[88].	In a 14-month-old boy with epileptic encephalopathy and intractable seizures, 
Veeramah et al. [9] identified a de novo hemizygous missense mutation in the CLCN4 gene 
by whole-exome sequencing. In vitro functional expression studies in Xenopus oocytes 
showed that the mutation almost abolished the outwardly rectifying currents, consistent with 
a loss of function. Fifty-two individuals from 16 families with CLCN4-related disorder were 
recently reported: 5 affected females and 2 affected males with a de novo variant in CLCN4 
and 27 affected males, 3 affected females and 15 asymptomatic female carriers from 9 
families with inherited CLCN4 variants.	A seizure disorder was reported in 15 males (52%) 
from seven families varying from infrequent seizures, well controlled with monotherapy 
(47%), to severe infantile-onset intractable epilepsy (53%), even within a family. Three 
seizure-related deaths were reported in one family, which may have resulted from limited 
antiepileptic treatment options. No particular antiepileptic medication was found to be 
consistently more effective in the eight families with seizure disorder [89]. 
 
DNM1-related epileptic encephalopathy  
The dynamin 1 gene (DNM1) encodes a large guanosine triphosphatase (GTPase), which 
plays a key role in clathrin-mediated synaptic vesicle endocytosis, particularly during post-
natal development [90]. A few cases with early-onset epileptic encephalopathy, including 
West syndrome and Lennox-Gastaut syndrome, have been described [6,91,92]. Not all 
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patients were reported as drug-resistant; one patient was seizure-free on vigabatrin and 
valproate from 3 to 8 years, one on ketogenic diet since age 3.5 years until last follow-up at 
age 6 years, one on clobazam and valproate from 3 to 5 years of age [6,92].	Dhindsa et al. 
[93]performed in vitro functional expression assays of three missense mutations in the DNM1 
gene; all caused impaired endocytosis of transferrin in a dominant-negative manner, although 
the mechanisms differed slightly. The findings were consistent with a defect in synaptic 
vesicle cycling and endocytosis, which none of the effective treatments probably target 
directly. 
 
DOCK7-related epileptic encephalopathy  
DOCK7 is a member of the DOCK180-related protein superfamily, which functions as a 
guanine nucleotide exchange factor (GEF) for Rac and/or Cdc42 GTPases. It plays a role in 
neurogenesis [94]. In three female patients (two affected female siblings born to 
nonconsanguineous healthy French Canadians parents and one affected female case born to 
nonconsanguineous healthy French parents) from two unrelated families with early infantile 
epileptic encephalopathy, Perrault et al. [95] identified four different (compound) 
heterozygous truncating mutations in the DOCK7 gene, predicted to result in a loss of protein 
function. The clinical syndrome included dysmorphism and cortical blindness, with 
intractable seizures with hypsarrhythmia despite the administration of multiple antiepileptic 
drugs in various combinations and the ketogenic diet [95]. 
 
EEF1A2-related epileptic encephalopathy  
The EEF1A2 gene encodes eukaryotic translation elongation factor-1, alpha-2, a protein that 
plays an essential role in protein synthesis by transporting aminoacyl-tRNA to the A-site of 
the ribosome [96]. Few cases with EEF1A2-related epileptic encephalopathy have been 
reported [9,27,96-98]. Sodium valproate was effective in three cases, in monotherapy or 
associated with zonisamide or lamotrigine [96,98]. Most cases had drug-resistant epilepsy. 
 
FOXG1-related epileptic encephalopathy  
The FOXG1 gene encodes a developmental transcription factor with repressor activities, and 
is involved in the transcription regulatory network that controls proliferation, differentiation, 
neurogenesis, and neurite outgrowth [99]. Duplications of FOXG1 have been associated with 
West syndrome [100,101].	There is evidence that infantile spasms in children with FOXG1 
duplications respond to hormonal therapy with ACTH [102,103], with cessation of clinical 
spasms and resolution of hypsarrhythmia on EEG.	Deletions or intragenic mutations manifest 
with a more severe phenotype, with	developmental delay, prominent dyskinetic movements, 
and drug-resistant epilepsy [103,104]. 
 
GABRA1/GABRB1/GABRB3/GABRG2-related epileptic encephalopathy 
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Mutations affecting the receptor gene family of heteromeric pentameric ligand-gated ion 
channels through which gamma-aminobutyric acid (GABA) acts have been associated with 
epileptic encephalopathies. The Epi4K Consortium and Epilepsy Phenome/Genome Project 
[5] found six mutations in subjects with infantile spasms or Lennox-Gastaut syndrome 
affecting subunits of the GABA ionotropic receptor (four in GABRB3, and one each in 
GABRA1 and GABRB1). Some de novo missense variants in GABRB1 and GABRB3 have 
been functionally characterized and shown	to	affect GABAA ligand-gated chloride channel 
function, either by reducing channel opening (Lennaux–Gastaut syndrome-related mutations 
in GABRB3), or by affecting opening/closing kinetics (infantile spasm-related mutations, one 
in GABRB1 and one in GABRB3)[105]. A further case with GABRB1-related epileptic 
encephalopathy has been recently reported and has shown a positive response (no further 
details on response available) to ketogenic diet [106]. Mutations in GABRB3 have been 
associated with various epileptic encephalopathies, including a ‘Dravet-like’ phenotype, 
myoclonic atonic epilepsy, West syndrome and Lennox-Gastaut syndrome [107]. Mutations 
in GABRA1 have also been associated with various epileptic encephalopathies, including a 
‘Dravet-like’ phenotype, ‘myoclonic atonic epilepsy-like’ phenotype, or other milder 
undefined epilepsy encephalopathy phenotypes [108,109]. One patient with a ‘Dravet-like’ 
phenotype was reported as seizure-free on levetiracetam monotherapy, and one patient with 
‘mild epileptic encephalopathy’ was seizure-free on valproate and levetiracetam combination 
therapy [109]. Similarly, mutations in	GABRG2 have been associated with Dravet syndrome, 
epilepsy with myoclonic-atonic, Lennox-Gastaut syndrome or other unclassified epileptic 
encephalopathies [110,111]. Shen et al.[111] reported two out of seven cases seizure-free on 
levetiracetam or on a combination of valproate and topiramate, respectively. Huang et al. 
[112] studied the GABRG2 nonsense mutation, Q40X, associated with Dravet syndrome. 
They found that the mutant subunit mRNA was degraded by nonsense-mediated mRNA 
decay, and the undegraded mutant mRNA was translated to a truncated peptide. They used an 
aminoglycoside, gentamicin, to rescue translation of intact mutant subunits by inducing 
mRNA read-through. In the presence of gentamicin, the cellular phenotype was partly 
rescued. These findings might direct future treatment strategies. 
 
GAMT/GATM-related epileptic encephalopathy 
Amidinotransferase converts glycine to guanidinoacetate; guanidinoacetate methyltransferase 
(GAMT) converts the latter to creatine with S-adenosylmethionine as the methyl donor. 
GAMT deficiency, also known as cerebral creatine deficiency syndrome-2, is an autosomal 
recessive inborn error of creatine synthesis. Its clinical features are developmental 
delay/regression, mental retardation, severe disturbance of expressive and cognitive speech, 
intractable seizures and movement disturbances, severe depletion of creatine/phosphocreatine 
in the brain, and accumulation of guanidinoacetic acid (GAA) in brain and body fluids [113]. 
Mikati et al. [114] found that epilepsy was present in 81% of patients with GAMT deficiency, 
with age at onset usually between 10 months and 3 years. Drug resistance was observed in 
approximately 45%. Epilepsy syndromes associated with GAMT deficiency include Lennox-
Gastaut and West syndrome. Current treatment options include oral high-dose creatine which 
significantly increases brain creatine concentrations [115], and dietary manipulation 
combining suuplementation of ornithine with restriction of arginine, to reduce 
guanidinoacetate toxicity [116]. Establishment of early treatment may prevent some features 
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of the condition from developing, i.e. intellectual disability [117]. There is evidence that also 
treatment in adults with GAMT deficiency can dramatically reduce seizure frequency [116]. 
The enzyme L-arginine: glycine amidinotransferase (GATM) catalyzes the transfer of a 
guanido group from arginine to glycine, forming guanidinoacetic acid, the immediate 
precursor of creatine [118].	GATM (or AGAT) deficiency, also known as cerebral creatine 
deficiency syndrome-3, is caused by homozygous mutation in the GATM gene. Its clinical 
phenotype is similar to the one caused by GAMT deficiency [113], but here most patients 
develop a myopathy characterized by muscle weakness and atrophy later in life. As for 
GAMT deficiency, early diagnosis and treatment with oral creatine supplementation can 
significantly improve the outcome [119,120]. 
 
GNAO1-related epileptic encephalopathy  
The GNAO1 gene encodes an alpha subunit of the heterotrimeric guanine nucleotide-binding 
proteins (G proteins), a large family of signal-transducing molecules. The phenotypic 
spectrum can vary from movement disorder with no or controlled seizures to early infantile 
epileptic encephalopathy, and Ohtahara syndrome, with drug-resistant epilepsy [6,121-123]. 
Nakamura et al.[121] reported four female cases with GNAO1 mutations, three with Ohtahara 
syndrome and one with unclassified epileptic encephalopathy: seizures and EEG findings 
were temporarily improved by treatment with ACTH and valproate in two cases with 
Ohtahara syndrome; however all four individuals had intractable epileptic seizures in spite of 
combinatory therapy of antiepileptic drugs. The EuroEPINOMICS-RES Consortium [6] 
reported two cases with GNAO1-related epileptic encephalopathy: one case with onset of 
infantile spasms at 3 months, seizure-free off treatment until the last follow-up at the age of 3 
years; another one with drug-resistant epilepsy with multiple seizure types. Saitsu et al.[123] 
reported two additional cases with GNAO1 mutations and early-onset epileptic 
encephalopathy, both with drug-resistant epilepsy. No further details on treatment are 
available. 
 
GRIN1/GRIN2A/GRIN2B-related epileptic encephalopathy 
The ionotropic glutamate N-methyl-D-aspartate (NMDA) receptors are tetrameric ligand-
gated ion channels permeable to sodium, potassium, and calcium, composed of two glycine 
binding GluN1 subunits and two glutamate-binding GluN2/3 subunits. GRIN2A encodes the 
GluN2A subunit, GRIN2B the GluN2B subunit, and GRIN1 the GluN1 subunit [124].	NMDA 
receptors have important roles in synaptogenesis and synaptic plasticity [125]. The epilepsy 
phenotype associated with GRIN1 mutation is highly variable. Treatment responsiveness also 
seems to vary: some patients were drug-resistant, two patients became seizure-free or had 
long periods of seizure freedom on valproate, one patient responded well to a combination of 
topiramate, levetiracetam, and clobazam and one other patient had good response following 
the introduction of vigabatrin and clonazepam in addition to valproate [126].		
The most common GRIN2A-related disorders are epilepsy-aphasia syndromes (EAS), a 
spectrum that includes: Landau-Kleffner syndrome (LKS); epileptic encephalopathy with 
continuous spike-and-wave during sleep (ECSWS); childhood epilepsy with centrotemporal 
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spikes (CECTS); atypical childhood epilepsy with centrotemporal spikes (ACECTS); and 
autosomal dominant rolandic epilepsy with speech dyspraxia (ADRESD) [127]. Other 
epilepsy phenotypes are: infantile-onset epileptic encephalopathy and unclassified childhood 
epilepsy [128-132]. Under physiological conditions, very few ions pass through the NMDA 
receptors because magnesium blocks the pore. When the NMDA receptor is activated, 
magnesium is displaced, and this allows calcium and other cations to move into the cell. In 
case of dysfunction of NMDA receptors, calcium influx into the cell increases. In vitro 
experiments showed that a specific GRIN2A mutant (L812M) receptor showed increased 
activity in response to agonists and decreased response to negative modulators [131]. 
Memantine, an NMDA receptor antagonist, was shown to inhibit the increased activity of the 
NMDA receptor caused by the L812M mutation, in vitro. A child with an early-onset 
epileptic encephalopathy due to the same GRIN2A missense mutation was treated with 
memantine added on to his antiepileptic medication, with subsequent significant 
improvement of seizure control and interictal EEG recordings [133]. A different GRIN2A 
missense mutation (N615K) causing a different channel dysfunction, with no effect on 
receptor activity, but acting through the relief of magnesium blockade, was found in another 
child with epileptic encephalopathy [128]. Due to the lack of effect of the mutation on the 
NMDA receptor activity, treatment with memantine was not tried in this case.	In another case 
with early-onset epileptic encephalopathy due GRIN2A mutation, addition of topiramate to 
levetiracetam and clonazepam, at 6 mg/kg/day, led to significant reduction of seizure duration 
and frequency within one month from more than a dozen seizures a day to one–two seizures 
per day, each lasting a few seconds, with good tolerability and improved alertness; this effect 
was sustained for ten months. The authors postulate that the benefit of topiramate could be 
explained through its action by enhancing the GABA-evoked currents [130]. 
GRIN2B mutations have been associated with West and Lennox–Gastaut syndromes [5,134]. 
The epilepsy is reported as generally drug-resistant, with some evidence in West syndrome of 
response to a combination of vigabatrin and pyridoxine, and later valproate, or steroid pulse 
therapy in two patients [134]. 
 
HCN1-related epileptic encephalopathy 
The gene HCN1 encodes one of the hyperpolarization-activated, cyclic nucleotide-gated 
(HCN) channels, expressed in both heart and brain [135].	In six unrelated patients with early 
infantile epileptic encephalopathy-24, Nava et al.[136] identified six different heterozygous 
missense mutations in the HCN1 gene.	The patients had seizure onset between 4 and 13 
months of age. Seizure type at onset tended to be tonic-clonic or hemiclonic but evolved into 
predominantly atypical absences with or without myoclonic jerks, and focal seizures, later in 
childhood. Epilepsy was described as drug-resistant in all cases. Four patients had status 
epilepticus. All patients had intellectual disability of varying degrees, and most had 
behavioral disturbances including autistic features.  
 
 
HNRNPU-related epileptic encephalopathy 
NRNPU has 14 exons, which are highly conserved during evolution. The gene encodes the 
heterogeneous nuclear ribonucleoprotein (hnRNP) U, that binds RNAs and mediates different 
aspects of their metabolism and transport [137,138]. More than 40 patients have been 
reported with deletions of the subtelomeric region of the long arm of chromosome 1 
(1q43q44 microdeletion syndrome) identified by chromosome microarray[139-142]. This 
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syndrome is associated with a complex neurological phenotype, including intellectual 
disability, microcephaly, epilepsy and anomalies of the corpus callosum HNRNPU is the 
main candidate for the epilepsy phenotype [139,142].  De novo and/or truncating mutations in 
HNRNPU causing epileptic encephalopathy have been reported [5,7,11,137,143], but details 
on the epilepsy phenotype are sparse. More recently, six patients with constitutive de novo, 
and one with mosaic frameshift, HNRNPU mutations and early-onset epilepsy were reported 
[142]. Seizure onset ranged from age 2.5 months to 4 years, and was within or at the first year 
of life in 5/6 patients. Fever was a factor triggering seizures in five patients. Seizures types 
included tonic–clonic, tonic, unilateral clonic or atypical absences occurring one to 20 times a 
day. Two patients experienced status epilepticus. Three of them were diagnosed with ‘non-
specific epileptic encephalopathy’. Lacosamide and valproate were described as ‘effective in 
two cases. 
 
IQSEC2-related epileptic encephalopathy 
The IQSEC2 gene is located on chromosome Xp11.22 and encodes a guanine nucleotide 
exchange factor for the ARF family of GTP-binding proteins [144]. IQSEC2is expressed in 
neurons and is involved in cytoskeletal organization, dendritic spine morphology, and 
excitatory synaptic organization [145]. All reported IQSEC2 variants are missense, nonsense 
or lead to splicing defects, resulting in reduced enzymatic activity [144,146]. Complete 
abolition of enzymatic activity causes a more severe phenotype in both males and females, 
with epileptic encephalopathy and nonsyndromic X-linked intellectual disability and epilepsy 
included in the phenotypic spectrum [147]. The first report of an IQSEC2-related epileptic 
encephalopathy, due to a de novo chromosomal translocation t(X; 20) (p11.2;q11.2) 
disrupting the IQSEC2 gene, was by Morleo et al.[148]: they reported a female case of West 
syndrome with spasms refractory to medical treatment. X-inactivation studies revealed an 
extremely skewed X-inactivation pattern with dominant use of the translocated X-
chromosome. Most cases of IQSEC2-related disorders were found by whole-exome or 
targeted capture sequencing in cohorts of patients with intellectual disability and/or epileptic 
encephalopathy [5,59,83,144,149-155]. Zerem et al. [147] described the phenotypic spectrum 
of 18 patients with IQSEC2-related epilepsy. Of these, 9 (50%) were diagnosed with epilepsy 
encephalopathies, including ‘late-onset epileptic spasms’ and ‘Lennox-Gastaut’ or ‘Lennox-
Gastaut-like syndrome’, all reported to have ‘intractable’ epilepsy except one case with 
Lennox-Gastaut syndrome where ‘response’ to lamotrigine and rufinamide is described. 
More recently, a family with four girls affected by probable IQSEC2-related epilepsy 
encephalopathy has been described, with two of them deceased due to probable SUDEP 
[146]. 
 
 
 
KCNA2-related epileptic encephalopathy 
The KCNA2 gene encodes the Kv1.2 channel, one of the voltage-gated potassium channels 
that are expressed in the central nervous system. The Kv1.2 channel belongs to the delayed 
rectifier class of potassium channels that enable efficient neuronal repolarization after an 
action potential [156]. De novo mutations in KCNA2 were identified as the cause of mild to 
severe epileptic encephalopathy [156-158]. Two patients with KCNA2 mutations associated 
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with early-onset epileptic encephalopathy had significant improvement of seizure control 
following introduction of acetazolamide [157,158], in keeping with observations in a mouse 
model [159]. Four patients with dominant-negative loss-of-function mutations had a 
phenotype overlapping with Dravet syndrome and epilepsy with myoclonic-atonic seizures. 
All four patients became seizure-free between four and 15 years old with no apparent 
association to a preceding change of medication. The phenotypes of two patients carrying 
mutations with dominant gain-of-function were more severe in terms of epilepsy with 
ongoing generalized tonic-clonic seizures despite treatment, ataxia and intellectual disability, 
and also differed electrographically, with generalized epileptic discharges [156].  
 
KCNB1-related epileptic encephalopathy 
The KCNB1 gene encodes the Kv2.1 channel, the main contributor to delayed rectifier 
potassium currents in pyramidal neurons of the hippocampus and cortex. All patients with 
KCNB1-related epileptic encephalopathy were reported to have refractory epilepsy [132,160-
163]. One patient had 6-month period of seizure freedom after implementation of the 
ketogenic diet, followed then by seizure recurrence [163].	A correlation between mutations 
that result in loss of Kv2.1 ion selectivity and development of epileptic encephalopathy has 
emerged [163]. 
 
KCNQ2/KCNQ3-related epileptic encephalopathy  
The KCNQ2 and KCNQ3 genes encode subunits of the voltage-gated potassium M channel 
underlying the neuronal M-current [164]. KCNQ2 mutations cause neonatal-onset epileptic 
encephalopathy of widely varying severity [165,166]. Affected individuals usually have 
multiple daily (mostly tonic) seizures beginning in the first week of life, with associated focal 
motor and autonomic features. Most cases have drug-resistant epilepsy; seizures then tend to 
generally cease by age nine months to four years [165]. Encephalopathy is present from birth 
and persists during and after the period when seizures are uncontrolled, with moderate to 
severe developmental impairment [5,7,165,167-172]. The most severe form of 
encephalopathy associated with KCNQ2 variants is Ohtahara syndrome, with typical 
suppression-burst EEG pattern within the first months of life and poor outcome in terms of 
psychomotor development and seizure control [10,173,174]. KCNQ3 variants also cause 
neonatal-onset epileptic encephalopathy [175,176]. 
In KCNQ2/KCNQ3-related epilepsy there is a potential tailored precision medicine strategy 
with the use of retigabine (ezogabine), a drug primarily acting as a positive allosteric 
modulator of KCNQ2-5 (Kv7.2-7.5) ion channels, and the first neuronal potassium (K+) 
channel opener licensed for the treatment of epilepsy [177]. In vitro studies identified the 
probable binding site of retigabine in KCNQ2 and KCNQ3 channels, explaining its voltage-
dependent activating effect through a hyperpolarizing shift of the activation curve [178,179]. 
Orhan et al.[180] defined the disease mechanism of seven de novo missense KCNQ2 
mutations associated with severe epileptic encephalopathy and found a clear loss of function 
for all the mutations studied in vitro. Most mutations showed a dominant-negative effect on 
wild-type KCNQ2 or KCNQ3 subunits. The use of retigabine partially reversed the loss of 
function, in vitro, for the majority of analyzed mutations. Preliminary data from humans with 
	 16	
KCNQ2-related disease suggest retigabine may be a useful treatment option [167,181]. 
However, mainly due to the discovery of additional side effects in the early post-marketing 
phase (blue discoloration of skin and retina), the production of retigabine will be soon 
discontinued, and it will be no longer commercially available. Sodium channel blockers also 
seem effective in KCNQ2-related epilepsy [166,167,172,174], possibly because voltage-gated 
sodium channels and KCNQ potassium channels co-localize and are bound at critical 
locations of the neuronal membrane [182]; the efficacy of sodium-channel blockers could be 
explained by the hypothesis that modulation of one channel may significantly affect the 
function of the channel complex [166]. Sodium channel blockers including carbamazepine 
and phenytoin should also be considered as first-line treatment in patients with KCNQ2-
related epilepsy, as there is a suggestion that early effective treatment reduces cognitive 
disability [17,172]. Treatment with vigabatrin or ACTH has been used for infantile spasms 
that can occur during the course of the disease [183-185]. A recent report described a positive 
effect of vitamin B6 on seizures in a few patients with KCNQ2-neonatal epileptic 
encephalopathy [186]; however, the underlying mechanism is unclear and needs further 
investigation. Some cases with KCNQ3-neonatal epileptic encephalopathy became seizure-
free on valproate monotherapy or on a combination of valproate and carbamazepine [176]. 
 
KCNT1-related epileptic encephalopathy  
The KCNT1 gene encodes a sodium-dependent potassium channel that is widely expressed in 
the nervous system. KCNT1 gain-of-function mutations are reported to cause early-onset 
epileptic encephalopathies (EOEE) including epilepsy of infancy with migrating seizures 
(approximately 50% of individuals with this syndrome have a KCNT1 pathogenic variant) 
[187-189]. Quinidine, an antiarrhythmic drug, is a partial blocker of KCNT1. It was 
previously used to reverse the hyperactivity of the mutant KCNT1 in Xenopus oocytes [190]. 
In two case reports of epilepsy of infancy with migrating seizures due to KCNT1 mutations, 
quinidine resulted in decreased seizure frequency or freedom from seizures and improved 
psychomotor development [187,189]. Another two cases with KCNT1-related epilepsy, one 
showing a novel phenotype with developmental regression and severe nocturnal focal and 
secondarily generalised seizures starting in early childhood, and the other with early-onset 
epileptic encephalopathy [189,191], did not respond to treatment with quinidine. More 
recently, a case of West syndrome caused by KCNT1 mutation was reported to show good 
response to quinidine, with reduction of epileptic spasm frequency, improvement of EEG 
activity and progress in development [192]. Currently the therapeutic effects of quinidine in 
KCNT1-related epilepsy remain largely unknown and more work is required, although it 
seems a promising treatment option for epilepsy due to gain-of-function mutations in KCNT1. 
 
KIAA2022-related epileptic encephalopathy  
The KIAA2022 gene maps to Xq13.3 and, when mutated, is known to cause severe 
intellectual disability in males [193]. KIAA2022 is highly expressed in fetal and adult brain; 
its expression in adult brain is predominantly in the cerebral cortex and the cerebellum [193]. 
KIAA2022 encodes two protein products: the primary 1516 amino acid protein X-linked 
Intellectual Disability Protein Related to Neurite Extension (XPN), and an unnamed 118 
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amino acid protein [194]. XPN regulates cell-cell and cell-matrix adhesion and cellular 
migration by modulating the expression of adhesion molecules in neural signaling pathways, 
and therefore has  a crucial role in neuronal development. [195,196]. Five male patients from 
four families with KIAA2022-related syndrome including epilepsy have been reported. The 
described epilepsy syndromes were ‘generalised epilepsy’ in two unrelated cases (with 
remission after age 2.5 years in one case and ‘response’ to valproate in another), West 
syndrome in two siblings (in one responsive to treatment, no further details given), and 
Lennox-Gastaut in one case (with absences and atonic seizures ‘responding’ to lamotrigine 
and valproate) [193,197]. 
More recently, 18 females have been reported with de novo loss of function mutations in 
KIAA2022 associated with intellectual disabilities and intractable epilepsy. Farach and 
Northrup [198] reported a 17-year-old female with short stature, microcephaly, severe 
intellectual disability, poor speech, epilepsy, and autistic behaviour. Her seizures did not 
respond to multiple antiepileptic medications and vagal nerve stimulation. At age 17 years, 
she had corpus callosotomy with ‘vast improvement in seizure frequency’; however, at the 
time of the publication, she was still experiencing daily seizures. de Lange et al. [199] 
reported 12 female cases with heterozygous de novo KIAA2022 mutations and  epilepsy; 
these cases included 11 with generalized epilepsy (mostly absences and myoclonic seizures) 
and one with focal epilepsy, all drug-resistant. Webster et al. [200] described five further 
female cases with heterozygous de novo KIAA2022 mutations and drug-resistant epilepsy, 
four with generalised epilepsies, and one with myoclonic-astatic epilepsy. 
 
MEF2C-related epileptic encephalopathy 
MEF2C belongs to the myocyte enhancer factor-2 (MEF2) family of transcription factors. It 
plays a pivotal role in myogenesis, development of the anterior heart field, neural crest and 
craniofacial development, and neurogenesis, among other functions [201].	MEF2C 
haploinsufficiency is a genetic syndrome known to occur in cases of microdeletion of the 
5q14.3 region and MEF2C mutations [202,203].	The syndrome is characterized by severe 
intellectual disability, absence of speech and limited walking abilities, hypotonia, epilepsy, 
stereotypic movements, minor brain malformations, and minor dysmorphic features 
[203,204].	There are forty-four cases of 5q14.3 microdeletion and nine patients with MEF2C 
mutations reported thus far [205]. In two cases with epileptic encephalopathy due to MEF2C 
mutations, epilepsy was well controlled: one case on monotherapy with valproate [203], one 
case on a combination of	lamotrigine and clobazam [205]. 
 
MOCS1/MOCS2-related epileptic encephalopathy 
MOCS1, MOCS2, MOCS3 and GPRN genes contribute to the synthesis of molybdenum 
cofactor, and the SUOX gene encodes sulfite oxidase. Molybdenum cofactor deficiency 
(MoCD) and Sulfite Oxidase Deficiency (SOD) are rare autosomal recessive disorders of 
sulfur-containing amino acid metabolism. The clinical phenotype is characterized by onset in 
infancy of poor feeding, intractable seizures, and severe psychomotor retardation. 
Characteristic biochemical abnormalities include decreased serum uric acid and increased 
urine sulfite levels due to the combined enzymatic deficiency of xanthine dehydrogenase 
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(XDH) and sulfite oxidase (SUOX), both of which use molybdenum as a cofactor. Most 
affected individuals die in early childhood [206,207]. A recent study showed that intractable 
neonatal seizures, spasticity, and feeding difficulties can be important early signs for these 
disorders [208]. Most patients have early-onset intractable seizures (generalized tonic clonic 
and multifocal myoclonic), not responding to antiepileptic medications. There is evidence of 
successful replacement therapy with cyclic pyranopterin monophosphate (cPMP), a 
biosynthetic precursor of the molybdenum cofactor, in patients with MOCS1 mutations (type 
A deficiency), in patients either diagnosed prenatally or very early in life, which showed 
favorable clinical and biochemical response [209,210]. 
 
NDP-related epileptic encephalopathy 
The NDP gene encodes norrin, a secreted cysteine-rich protein that belongs to the cystine 
knot growth factor family [211]. NDP mutations cause Norrie disease, an X-linked recessive 
disorder that is characterized by congenital blindness, which is often accompanied by greyish 
yellow fibrovascular masses (pseudogliomas) secondary to retinal vascular dysgenesis and 
detachment [212]. The extraocular clinical manifestations of Norrie disease include epilepsy, 
which is reported in ∼10% of patients [213]. There are only a few reports with details of the 
epilepsy phenotype in Norrie disease [214,215]. One case with Norrie disease and severe 
neurological involvement including infantile spasms was reported by Lev et al.[214]; they 
describe a significant improvement of the spasms, but not of the EEG, on a combination of 
topiramate and clonazepam. 
 
PCDH19-related epileptic encephalopathy 
PCDH19 encodes protocadherin-19, a calcium-dependent cell adhesion molecule expressed 
throughout the central nervous system and involved in brain development, intracellular 
signaling, and synaptogenesis [216]. Mutations cause early infantile epileptic 
encephalopathy-9, or epilepsy and mental retardation limited to females (EFMR) [216]. The 
most typical phenotype seen in EFMR females comprises a normally-developing infant 
whose seizures begin under 3 years (mean age of 14 months), sometimes with developmental 
regression at seizure onset. Two thirds of affected females have borderline intellect or 
intellectual disability, which varies from mild to profound; autistic features may be prominent 
[217]. PCDH19 mutations can also cause a ‘Dravet-like’ phenotype, although with later age 
of onset, less frequent status epilepticus, myoclonic and absence seizures, and a lesser degree 
of intellectual disability, than cases with SCN1A-related Dravet syndrome [218]. Hemizygous 
“carrier” males are usually asymptomatic or exhibit only psychiatric or behavioural 
symptoms [217]. However, two male cases with somatic mosaicism for PCDH19 deficiency 
have been reported so far; both had epileptic encephalopathy with uncontrolled seizures, 
although improvement of motor development was reported on levetiracetam [218,219]. Data 
on epilepsy course and treatment are sparse. Seizures appear to be highly resistant to 
antiepileptic drug treatment during the first years of life, while their frequency and their 
pharmacoresistance tend to decrease during the course of the disease [220]. Depienne et 
al.[218] reported 3 out of 13 cases with a ‘Dravet-like’ phenotype that had seizure control on 
a combination of valproate and lamotrigine; valproate, clobazam and topiramate; or 
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valproate, clobazam and stiripentol. Hynes et al. [221] report two affected sisters and one 
sporadic female with EFMR: one of the siblings became seizure-free on a combination of 
valproate and clobazam, and she was weaned off antiepileptic treatment at 13.5 years; the 
other siblings achieved seizure control on a combination of levetiracetam, carbamazepine and 
lamotrigine; the sporadic case had episodes of convulsive status epilepticus which responded 
to phenytoin in combination with lamotrigine and clobazam. Also in a single case report, a 
combination of valproate, clobazam and stiripentol, was reported to be effective [222]. 
Higurashi et al. [223] reported effectiveness of phenytoin, bromide and clobazam, in 
monotherapy or combination. A recent retrospective multicenter study in 58 females with 
EFMR found that clobazam and bromide were the most effective drugs, with 74% of the 
cases who became seizure-free for at least for three months and 47% for at least one year. 
The typical loss of effectiveness of clobazam after several months of treatment was not 
observed [224]. Tan et al.[225] showed that defective neurosteroid metabolism is associated 
with EFMR, as they found dysregulation of the AKR1C genes, which code for crucial 
neurosteroid-metabolizing enzymes, causing subsequent allopregnanolone deficiency. This 
finding may represent a promising precision medicine approach with a novel therapeutic 
target in EFMR. 
 
PIGA/PIGQ-related epileptic encephalopathy  
PIGA and PIGQ encode proteins involved in the biosynthesis of the 
glycosylphosphatidylinositol (GPI) anchor, a glycolipid structure embedded in the plasma 
membrane that attaches dozens of different proteins to the cell surface [226,227]. Four cases 
with early myoclonic encephalopathy, West syndrome, or unclassified early-onset epileptic 
encephalopathies, all with intractable seizures, were found to have PIGA mutations [228]. 
One case with Ohtahara syndrome was found to have PIGQ mutation [10]. 
 
PLCB1-related epileptic encephalopathy  
The PLCB1 gene encodes a mammalian isoform of the phospholipase C-beta which catalyzes 
the generation of inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 
4,5-bisphosphate, a key step in the intracellular transduction of many extracellular signals 
[229]. Homozygous or compound heterozygous loss-of-function PLCB1 mutations have been 
described in four children with early-onset epileptic encephalopathies, including one with 
epilepsy of infancy with migrating focal seizures [230-233]. Epilepsy was drug-resistant in 
all cases, with some evidence of non-sustained improvement in seizure control on 
phenobarbitone and prednisolone [230], ketogenic diet [232], or valproate [233]. 
 
PNKP-related epileptic encephalopathy  
The PNKP gene encodes a polynucleotide kinase 3-prime phosphatase, which is involved in 
the DNA repair pathway [234]. Biallelic mutations in this gene cause autosomal recessive 
microcephaly with early-onset intractable seizures and developmental delay [235].	This 
condition has a range of phenotypic severity: some patients have a disease course consistent 
with early infantile epileptic encephalopathy, whereas others have more well-controlled 
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seizures and a protracted course associated with cerebellar atrophy and peripheral neuropathy 
[235,236]. Among cases with epileptic encephalopathy, one had seizures well controlled on 
phenobarbital and levetiracetam [237]; epilepsy surgery was underataken in two cases, one 
with undefined outcome, one with recurrent seizures after surgery [235]; the other cases had 
drug-resistant epilepsy [235]. 
 
PNPO-related epileptic encephalopathy 
Pyridox(am)ine-5-phosphate oxidase (encoded by the PNPO gene) deficiency is an 
autosomal recessive disorder of pyridoxine metabolism. PNPO deficiency is a treatable cause 
of neonatal epileptic encephalopathy [238]. The pyridox(am)ine-5-phosphate oxidase enzyme 
converts pyridoxine-5-phosphate and pyridoxamine-5-phosphate to pyridoxal 5′-phosphate 
(PLP; the only active form of vitamin B6), and is necessary for the recycling of PLP [239], 
seizures in PNPO deficiency are usually resistant to pyridoxine but respond to pyridoxal 5′-
phosphate [240], although several pyridoxine-responsive patients have been reported 
[241,242]. Mills et al. [238] showed that mutations in PNPO led to reduced enzyme activity 
when expressed in Chinese hamster ovary cells. 
 
POLG-related epileptic encephalopathy  
The POLG gene encodes the mitochondrial DNA polymerase. POLG mutations were first 
identified in a family segregating autosomal dominant progressive external ophthalmoplegia 
[243]. Since then, the phenotypic spectrum has considerably broadened, including dominant 
or, more often, recessive diseases. The most severe presentation is Alpers-Huttenlocher 
syndrome characterized by childhood-onset progressive and ultimately severe 
encephalopathy with intractable epilepsy and hepatic failure [244]. Most syndromes 
associated with POLG mutations have usually later onset, ranging from adolescence to 
adulthood, including spinocerebellar ataxia with epilepsy (SCAE), mitochondrial recessive 
ataxia syndrome (MIRAS), sensory ataxic neuropathy with dysarthria and ophthalmoplegia 
(SANDO), myoclonus, epilepsy, myopathy, sensory ataxia (MEMSA), mitochondrial 
encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), chronic intestinal 
pseudo-obstruction, occipital lobe epilepsy with status epilepticus, non-syndromic childhood-
onset intractable epilepsy, Charcot-Marie Tooth-like disease, and autosomal dominant distal 
myopathy [245]. Alpers-Huttenlocher syndrome is a progressive disorder and often leads to 
death from hepatic failure or status epilepticus before the age of three years [246]. Liver 
dysfunction can be present at the onset of the neurologic symptoms, or it can begin following 
treatment with valproate for seizure control [247]. Children with POLG1 mutations can also 
present with isolated encephalopathy, which can be progressive or fluctuating, and liver 
dysfunction can be absent. Seizures and cortical blindness are common clinical 
manifestations.	Epilepsy is a factor influencing mortality in patients with POLG1 mutations 
[248]. The combination of early encephalopathy, epilepsy, hepatopathy, and sensory axonal 
neuropathy was found in patients with recessive mutations in the mtDNA helicase Twinkle 
(PEO1), underlining the similarity of clinical phenotypes caused by either PEO1 or POLG1 
mutations [249]. Similarly to the POLG1-associated Alpers syndrome, also these patients 
display mtDNA depletion. Severe elevation of the liver enzymes followed initiation of 
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valproate treatment in some of these patients. Therefore valproate should be avoided in all 
patients with POLG1- related disorders and Twinkle-associated epileptic encephalopathy due 
to the risk of fatal valproate hepatotoxicity [250]. Epilepsy, including epilepsia partialis 
continua, is usually drug-resistant and there are no antiepileptic drugs demonstrated with 
clear effectiveness for seizure control in POLG-associated epileptic disorders. 
 
QARS-related epileptic encephalopathy  
The gene QARS encodes glutaminyl-tRNA synthetase, an enzyme that charges tRNAs with 
their cognate amino acids [251]. Compound heterozygous mutations in the QARS gene have 
been identified in a few cases with early-onset epileptic encephalopathies [252-255]. Most 
cases had drug-resistant epilepsy. However, in one case, valproate was able to control 
generalized tonic seizures; in another case combination therapy with phenobarbital, 
potassium bromide, valproate, and clobazam controlled seizures [253]. More recently in a 
further case, the ketogenic diet was reported to significantly improve seizure control with 
reduced duration and clustering of seizures, and improved cognition [255]. 
 
 
SCN1A-related epileptic encephalopathy  
SCN1A encodes the voltage-gated sodium channel type I alpha subunit. SCN1A-related 
seizure disorders encompass a spectrum that ranges from simple febrile seizures and 
generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome 
and other epileptic encephalopathies at the severe end. Phenotypes with intractable seizures 
include Dravet syndrome, epilepsy with myoclonic-atonic seizures, Lennox-Gastaut 
syndrome, infantile spasms, and epilepsy of infancy with migrating focal seizures [256-260].	
Dravet syndrome is a severe genetic epileptic encephalopathy with onset in infancy, often 
associated with drug-resistant epilepsy, developmental slowing, cognitive impairment, 
occurrence of status epilepticus, and elevated risk of early mortality[261]. It is caused by 
mutations in the SCN1A gene in approximately 80-90% of cases (of these >90% occur de 
novo, and 5 to10% are inherited)[260,262]. Adjustment of treatment in Dravet syndrome may 
be associated with improved seizure control, cognition and quality of life, even into later 
adult life[263]. Sodium channel blockers, e.g. carbamazepine, oxcarbazepine and phenytoin, 
should usually be avoided as they can aggravate both seizures and interictal EEG [264]. 
Lamotrigine can also cause seizure exacerbation [265], though has been reported to be 
beneficial in some cases [266]. Treatment strategies with some evidence of positive effect 
include valproate, clobazam, topiramate, levetiracetam, fenfluramine and bromides [267-271] 
or dietary therapies (ketogenic or modified Atkins diet) [272]. There are ongoing studies on 
the use of cannabidiol in children with Dravet syndrome. A recent open-label interventional 
trial of the use of cannabidiol in drug-resistant epilepsy included mostly patients with Dravet 
and Lennox-Gastaut syndromes: a post-hoc analysis revealed significant reduction in monthly 
frequency of all seizure types in patients with Dravet syndrome [273]. Randomised, double-
blind, multicenter clinical trials are needed to clearly establish the effectiveness and safety 
profile of cannabidiol in patients with Dravet syndrome [274]. Stiripentol is the only 
treatment for which a randomised, placebo-controlled, trial has been performed in children 
with Dravet syndrome [275] showing that significantly more children with Dravet syndrome 
on stiripentol (in add-on to valproate and clobazam) therapy were seizure-free, or 
experienced at least a 50% reduction in seizure frequency, compared to placebo. However, 
the use of stiripentol, valproate and clobazam does not always yield complete seizure 
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freedom and may cause adverse side effects [276,277]. Thalamic deep brain stimulation 
(DBS) was reported by Andrade et al.[278] in two children with Dravet syndrome with ten-
year follow up; one showed “marked improvement” after implantation, whereas the other 
received no benefit. The “interneurone hypothesis” is currently the best-supported 
pathophysiological explanation of Dravet Syndrome. According to this hypothesis, SCN1A 
mutation results in reduced function of GABAergic inhibitory interneurons, leading to an 
overall excessive neuronal excitation[279]. However, other studies using Dravet Syndrome 
patient-derived induced pluripotent stem cells (iPSC) found increased excitability of both 
GABAergic and glutamatergic isolated neurons [280]. A recent study identified a 
depolarizing GABA phenomenon, and explored the mechanism of action of benzodiazepines 
and stiripentol, by using a physiology-based computational model [281].	Heterologous 
expression systems, in which cloned sodium channel α-subunits are expressed in an 
intrinsically non-excitable cell, were the first models used to investigate the cellular 
consequences of SCN1A mutations associated with epilepsy, and were the first to demonstrate 
that SCN1A mutations can cause both gain and loss of function at the channel level [282]. 
There is increasing evidence that epileptogenic SCN1A mutations cause mainly loss of 
function, whereas familial hemiplegic migraine is caused by gain of function mutations [283]. 
Heterologous expression systems have been used for testing compounds that modulate 
voltage-gated sodium channels. For example, ranolazine, a U.S. Food and Drug 
Administration (FDA)-approved drug for chronic angina treatment, was first identified as a 
selective blocker of persistent currents in mutant NaV1.1 channels expressed in one of these 
models [284]. In follow-up studies in cultured rat hippocampal neurons, ranolazine was found 
to reduce neuronal excitability and suppress epileptiform activity evoked by NMDA receptor 
activation [285]. A more recent study showed that ranolazine does not inhibit the persistent 
Na+ current more strongly than phenytoin in central neurons, but is a better use-dependent 
blocker of transient Na+ current than phenytoin [286]. Furthermore, identifying compounds 
that can differentially modulate different subtypes/isoforms of sodium channels may 
contribute to identifying new treatment strategies for SCN1A-related epilepsy [287].	Baraban 
et al.[288] characterised zebrafish Nav1.1 (scn1Lab) mutants originally identified in a 
chemical mutagenesis screen using the optokinetic response as an assay [289]. The zebrafish 
scn1Lab gene shares a 77% identity with human SCN1A and is expressed in the central 
nervous system. Baraban et al. [288] demonstrated that mutants exhibit hyperactivity, 
including convulsive behaviour, spontaneous electrographic seizures, shortened lifespan and 
a pharmacological profile similar to the human condition. They then used the validated model 
in a novel high-throughput screening program to identify compounds that ameliorated the 
epilepsy phenotype. The strategy identified clemizole, a US Food and Drug Administration 
(FDA)-approved compound but not a licensed antiepileptic drug, as an effective inhibitor of 
spontaneous convulsive behaviour and electrographic seizures in these mutants. A recent 
study demonstrated that clemizole binds to serotonin receptors and its antiepileptic activity 
can be mimicked by drugs acting on serotonin signalling pathways; based on these findings, 
five patients with Dravet syndrome and drug-resistant epilepsy were treated with lorcaserin, a 
clinically-approved serotonin receptor agonist, with subsequent reductions in seizure 
frequency and/or severity [290]. 
Another example of serotonergic receptors modulation as a promising therapeutic target in 
Dravet Syndrome is fenfluramine [270,291]. This drug was initially developed as an appetite 
suppressant, but withdrawn from the market due to serious adverse effects, including valvular 
heart disease and pulmonary hypertension [292,293]. Fenfluramine has serotoninergic effects 
[294] but the exact anti-seizure mechanism has not been elucidated yet. Fenfluramine 
significantly reduced epileptiform dischardes in scn1Lab morphants in recent studies 
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[295,296]. Currently there are four ongoing clinical trials to evaluate the effectiveness and 
tolerability of this drug in Dravet Syndrome.  
 
SCN1B-related epileptic encephalopathy  
The SCN1B gene encodes the sodium channel beta1 subunit, which is an immunoglobulin-
like protein that is non-covalently linked to a voltage-gated sodium channel alpha subunit 
[297]. Two cases with Dravet syndrome have been found to have homozygous SCN1B 
mutations so far, both with drug-resistant epilepy [298,299]. 
 
SCN2A-related epileptic encephalopathy  
The SCN2A gene encodes the alpha2 subunit of the neuronal sodium channel, which is 
predominantly expressed in principal neurons of the hippocampus and cerebral cortex during 
early development [300]. SCN2A variants have been associated with epilepsy of infancy with 
migrating focal seizures or other severe epileptic encephalopathies, including Ohtahara 
syndrome (approximately 10% of individuals with Ohtahara syndrome have a SCN2A 
pathogenic variant) [301-304]. All SCN2A-associated disorders are known to be autosomal 
dominant in inheritance, and mutations associated with severe disease are often found to be 
de novo [304]. Sodium channel blockers have shown significant effectiveness in SCN2A-
epileptic encephalopathies [303-306]. This represents a potential precision medicine 
treatment: the mechanism of the effect has not been elucidated yet, but, as might be expected, 
the effect seems mostly present in patients with gain-of-function mutations. Another 
hypothetical precision medicine treatment was recently reported in an anecdotal case with a 
de novo SCN2A splice site mutation associated with epileptic encephalopathy, early-onset 
global developmental delay, intermittent ataxia, autism, hypotonia, and cerebral/cerebellar 
atrophy. In the cerebrospinal fluid, both homovanillic acid and 5-hydroxyindoleacetic acid 
were significantly decreased; extensive biochemical and genetic investigations ruled out 
primary neurotransmitter deficiencies and other known inborn errors of metabolism. 
Treatment with oral 5-hydroxytryptophan, l-Dopa/Carbidopa, and a dopa agonist resulted in 
reduced seizure frequency and “some EEG improvement” (on a stable dose of valproate and 
ethosuximide), most likely via dopamine and serotonin receptor-activated signal transduction 
and modulation of glutamatergic, GABA-ergic and glycinergic neurotransmission [307]. Two 
other anectodal cases, with SCN2A-related early infantile epileptic encephalopathy and drug-
resistant epilepsy, were treated with intravenous lidocaine and then transitioned to enteral 
mexiletine. This treatment led to improvement in seizure control in both cases: in one case 
seizure frequency decreased from more than 100 daily clinical events to two on average, with 
evidence of correlation of seizure control with mexiletine levels; in the other case seizures 
fell from daily to weekly frequency. Both lidocaine and mexiletine are classified as 1b 
antiarrhythmic drugs that block the fast activation of sodium channels in cardiac muscle; as 
they drugs cross the blood-brain barrier, a similar mechanism in neuronal circuits, may 
explain their potential effect on seizure control [308]. 
 
SCN8A-related epileptic encephalopathy  
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SCN8A encodes the voltage-dependent sodium channel Nav1.6, located in both inhibitory and 
excitatory neurons [309]. SCN8A-related epileptic encephalopathy is characterized by 
developmental delay, seizure onset in the first 18 months of life, and intractable epilepsy with 
multiple seizure types. Associated epilepsy syndromes can include Lennox-Gastaut, West, 
Dravet and Ohtahara. To date epileptic encephalopathy associated with a de novo SCN8A 
pathogenic variant has been reported in the literature in about 50 individuals (0.6-2.4% of 
cases with early infantile epileptic encephalopathy) [5,7,83,91,154,309-323]. In most tested 
cases, SCN8A mutations showed a gain-of-function effect [309,324]. Sudden unexpected 
death in epilepsy (SUDEP) has been reported in approximately 10% of published cases 
[310,312,318,319]. To reduce the risk of SUDEP, it is critical to improve seizure control. 
There is clinical evidence of a possible effective precision medicine approach in using 
sodium channel blockers to treat patients with SCN8A-related epilepsy; these drugs include 
phenytoin, carbamazepine, lacosamide, lamotrigine, rufinamide, and oxcarbazepine 
[319,322,325]. The effectiveness of sodium channel blockers is consistent with the activating 
effects of most SCN8A pathogenic variants [309,326,327]. Also valproate has been reported 
to be effective, possibly through modulation of sodium channel activity [309,319,326]. Most 
patients are maintained on multiple medications with incomplete seizure control. One study 
of four patients reported a positive response to high doses of phenytoin:	all of them had been 
drug-resistant; three became seizure-free and one had dramatic reduction of seizure frequency 
and severity after the initiation of phenytoin treatment[322].  
 
SETBP1-related epileptic encephalopathy  
De novo dominant mutations of the SET binding protein 1 (SETBP1) gene are known to 
cause Schinzel-Giedion syndrome, a highly recognizable syndrome characterized by severe 
mental retardation, distinctive facial features, and multiple congenital malformations 
including skeletal abnormalities, genitourinary and renal malformations, and cardiac defects, 
as well as a higher-than-normal prevalence of tumours [328]. West syndrome has been 
reported in association with Schinzel-Giedion syndrome, with seizures being extremely 
resistant to treatment with antiepileptic drugs and ketogenic diet [329-331]. Only one patient 
was reported to be responsive (to phenobarbital), but no long-term follow-up is available 
[332], and one had hypsarrhythmia at the age of 7 months of age, which was temporarily 
controlled by ACTH treatment for five weeks [333]. 
 
SIK1-related epileptic encephalopathy  
The SIK1 gene encodes a member of the AMP kinase subfamily with several roles in the 
central nervous system including regulation of the circadian clock [334] and transcription of 
corticotropin-releasing hormone in the hypothalamus [335]. Six different de novo 
heterozygous SIK1 mutations were found in six unrelated children with early myoclonic 
encephalopathy, infantile spasms or Ohtahara syndrome. All subjects had intractable seizures. 
None of the subjects with infantile spasms responded to ACTH [336]. 
 
SLC12A5-related epileptic encephalopathy  
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The SLC12A5 gene encodes the neuronal potassium-chloride cotransporter 2 (KCC2) that is 
the major extruder of intracellular chloride in mature neurons, and is exclusively expressed in 
the central nervous system [337]. Compound heterozygous or homozygous missense 
mutations in the SLC12A5 gene have been found in eight children from five unrelated 
families with epilepsy of infancy with migrating focal seizures. One of these patients had 
marked reduction in seizure frequency and no evidence of epileptiform activity on EEG 
following treatment with steroids (intravenous methylprednisolone for three consecutive days 
followed by oral prednisolone); further improvement of seizure control was achieved with the 
introduction of ketogenic diet and prednisolone was withdrawn, then tapering of the 
ketogenic diet was associated with a moderate rise in seizure frequency and the patient was 
on valproate and clobazam at the latest follow-up with ongoing seizures; the affected sibling 
did not respond to steroid treatment but had unspecified response to ketogenic diet; ketogenic 
diet was effective in one further unrelated case; one case had improvement of seizure control 
on a combination of phenobarbitone and topiramate; the combination of potassium bromide 
and high-dose phenobarbital was effective for two other cases; two patients had intractable 
seizures despite multiple antiepileptic drugs [337,338].	
 
SLC13A5-related epileptic encephalopathy  
The SLC13A5 gene encodes a plasma membrane sodium-dependent citrate transporter [339]. 
In the brain, the transporter is expressed mostly in neurons. As astrocytes secrete citrate into 
extracellular medium, the potential function of SLC13A5 in neurons is to mediate the uptake 
of circulating citrate and astrocyte-released citrate for subsequent metabolism [340]. The 
phenotype of SLC13A5-related epileptic encephalopathy is characterised by seizure onset 
within the first weeks after birth, developmental delay, slow progression of motor function, 
significant impairment in language and speech development, fever sensitivity, early 
occurrence of status epilepticus (hemiconvulsive, convulsive and non-convulsive), defects 
in tooth development, and punctate white matter lesions on neonatal MRI (no longer 
visible at the age of 6 months, but lead to gliotic scarring visible on MRI at the age of 18 
months) [341-344]. Three patients reportedly ‘responded well’ to ketogenic diet, although 
they had to stop the diet due to side effects or compliance issues, whilst four had seizure 
worsening or no benefit from the diet [342-344]. Epilepsy surgery was undertaken in one 
patient, without success [343].	Some improvement in response to drugs that affect GABA 
signaling, including including diazepam, lorazepam, phenobarbital, clonazepam, clobazam 
and midazolam, and sodium channel blockers, including phenytoin, lamotrigine and 
lidocaine, has been reported. However, phenytoin worsened myoclonus in one patient 
[343,344]. Acetazolamide decreases urinary citrate excretion by inducing metabolic acidosis 
[345], and this should increase citrate reabsorption by the renal NaDC1 transporter 
(SLC13A2) [346]: it was reported to improve seizure control without evidence of acidosis 
[343]. Recently biallelic SLC13A5 mutations have been found to cause Kohlschütter–Tönz 
syndrome, a rare autosomal-recessive disease characterised by epileptic encephalopathy, 
developmental delay or regression and yellowish discolouration of the teeth due to 
amelogenesis imperfect [347]. 
 
SLC2A1-related epileptic encephalopathy  
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Glucose transport 1 (GLUT-1) deficiency is a genetic metabolic encephalopathy caused by a 
decrease in the transfer of glucose to the brain due to mutations in the glucose transporter 1 
(SLC2A1) gene. GLUT-1 deficiency shows wide phenotypic pleiotropy, including delayed 
neurologic development, dysarthria, acquired microcephaly, complex movement disorder 
including ataxia, dystonia and chorea, and drug-resistant epilepsy, as antiepileptic drugs 
usually fail to control seizures [348]. Epilepsy syndromes include epilepsy with myoclonic-
atonic seizures, caused by SLC2A1 mutations in 5% cases [349], early-onset absence epilepsy 
[350], genetic generalized epilepsy [351], and more rarely West syndrome [352]. GLUT-1 
deficiency syndrome represents an established example of the application of the precision 
medicine concept. The gold standard treatment is the ketogenic diet, which provides ketones 
as an alternative fuel for cerebral metabolism, thereby treating the symptoms of 
neuroglycopenia [353]. Early diagnosis and initiation of the ketogenic diet are crucial to 
improve brain metabolism and seizure control [354], although the benefit on 
neurodevelopment seems controversial [348]. Certain antiepileptic drugs may be relatively 
contraindicated as adjunctive treatment in children on the ketogenic diet, for example 
valproate may inhibit Glut1 transport and beta-oxidation of fatty acids [355]. 
 
SLC25A22-related epileptic encephalopathy  
SLC25A22 encodes a mitochondrial glutamate/H+ symporter [356]. Mutations in this gene 
have been associated with early neonatal or infantile epileptic encephalopathy, including 
early myoclonic encephalopathy and Ohtahara syndrome [357-359], and epilepsy of infancy 
with migrating seizures [360]. Seizures were refractory to multiple antiepileptic drugs in all 
reported cases. 
 
SLC35A2-related epileptic encephalopathy 
The gene SLC35A2 at Xp11.23 encodes the Golgi-localized Uridine diphosphate (UDP)-
galactose transporter	at Xp11.23. Mutation of this gene causes congenital disorders of 
glycosylation due to UDP-galactose deficiency in the endoplasmic reticulum-Golgi network, 
resulting in reduced galactosylation of glycoproteins, glycosphingolipids and proteoglycans 
[361]. Five females with an SLC35A2 mutation, and two males with somatic mutation	
causing early-onset epileptic encephalopathy, have been reported so far [362-365]. The 
epilepsy is characterised by tonic partial seizures or epileptic spasms, initially. EEGs of all 
female patients showed hypsarrhythmia. Five patients were treated with ACTH: two had 
almost complete seizure remission; the other three patients had transient remission for several 
months or years, although seizures recurred thereafter. One patient achieved complete seizure 
remission after a second course of ACTH therapy, with subsequent improvement of 
development [362,364,365]. 
 
SLC6A1-related epileptic encephalopathy 
The SLC6A1 gene encodes one of the major GABA transporters in the brain, GAT-1, which 
removes GABA from the synaptic cleft [366]. Epilepsy with myoclonic-atonic seizures is 
caused by SLC6A1 mutation in 4% of cases [367]. Evidence of some response is reported to a 
combination of clonazepam and valproate, or of levetiracetam, clonazepam, and 
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ethosuximide, for control of atonic seizures [367]. One patient was seizure free for 3.5 years 
on clobazam [367]. The ketogenic diet was effective in two cases [367,368].  
 
SLC9A6-related epileptic encephalopathy 
The SLC9A6 gene, (also known as NHE6) on chromosome Xq26, encodes a monovalent 
sodium-selective sodium/hydrogen exchanger (NHE) that participates in a wide array of 
essential cellular processes, including control of intracellular pH, maintenance of cellular 
volume, and reabsorption of sodium across renal, intestinal, and other epithelia [369]. 
Mutations in SLC9A6 cause Christianson syndrome, an X-linked neurodevelopmental and 
progressive mental retardation syndrome, characterized by microcephaly, impaired ocular 
movements, severe global developmental delay, developmental regression, hypotonia, 
abnormal movements, and early-onset seizures of variable types. Female carriers may be 
mildly affected [370,371]. Epilepsy phenotypes in Christianson syndrome include Lennox-
Gastaut Syndrome and infantile spasms. No effective antiepileptic treatment has been 
described so far [371,372]. A spontaneous mutation in Nhe1 was found in the slow-wave 
epilepsy mouse with a neurological syndrome including ataxia and a unique epilepsy 
phenotype consisting of 3/sec absence and tonic-clonic seizures; mutants showed selective 
neuronal death in the cerebellum and brainstem [373]. There are indicators from several 
experimental studies that NHE inhibitors could be of significant value as potential 
anticonvulsants [374]. 
 
SPTAN1-related epileptic encephalopathy 
The SPTAN1 gene encodes nonerythrocytic alpha-spectrin-1, which has been shown to be 
essential for proper axon myelination of both peripheral and central nervous systems, in 
zebrafish [375]. SPTAN1 mutations have been report to cause epileptic encephalopathies, 
including West syndrome. Seizures were reported as refractory to various antiepileptic and 
hormonal therapies. In two patients, ACTH therapy was partially effective, and another 
patient partially responded to a ketogenic diet [376-379]. 
 
STX1B-related epileptic encephalopathy 
The gene STX1B encodes one of the syntaxins (syntaxin 1B) that are cellular receptors for 
transport vesicles. STX1B is directly implicated in the process of calcium-dependent synaptic 
transmission in rat brain [380]. Mutations in STX1B cause fever-associated epilepsy 
syndromes with a remarkably wide phenotypic spectrum, ranging from simple febrile 
seizures to severe epileptic encephalopathies [381]. In particular, Schubert et al.[381] 
described two cases with STX1B mutation end epileptic encephalopathies: one with epilepsy 
with myoclonic-atonic seizures shifting to Lennox-Gastaut syndrome, with initially 
intractable seizures and then seizure-free at the age of 7 years on levetiracetam, stiripentol 
and a vagus nerve simulator; one with myoclonic-astatic epilepsy on monotherapy with 
valproate, with unknown seizure response. A further case with myoclonic-astatic epilepsy, 
showing good response to treatment with valproate, has been recently reported [382]. 
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STXBP1-related epileptic encephalopathy  
Heterozygous mutations in the syntaxin-binding protein 1, STXBP1, gene which encodes 
Munc18-1, a core component of the presynaptic membrane-fusion machinery, have been 
observed in patients with severe forms of early-onset epileptic encephalopathy [383-387].  
STXBP1-related encephalopathy is characterized by early-onset refractory epilepsy with 
median age of onset of seizures of six weeks (range 1 day to 13 years) and moderate to severe 
intellectual disability. Epilepsy syndromes reported to be associated with STXBP1 variants 
include: Ohtahara (approximately 30% of individuals with Ohtahara syndrome have a 
STXBP1 pathogenic variant) [8,132,384,388-392], West (approximately 2% of individuals 
with West syndrome have a STXBP1 pathogenic variant) [5,383,388,389,391,393-395], 
Lennox-Gastaut [5],  Dravet syndrome without SCN1A mutation [108], and Rett (3 cases 
reported so far), either classic, not MECP2-related, or atypical Rett, not CDKL5-related 
syndromes[154,395,396]. 
The most commonly used antiepileptic drugs reported to have been used are phenobarbital, 
valproate, and vigabatrin [397]. Clobazam, zonisamide, lamotrigine, and oxcarbamazepine 
have also been used. In more than 20% of affected individuals, two or more antiepileptic 
drugs were used in combination. About 25% of affected individuals were reported to have 
drug-resistant epilepsy, whilst approximately 20% of affected individuals had seizures well 
controlled with one or more antiepileptic drugs [397]. In individuals who became seizure-
free, antiepileptic drugs were discontinued between one month and 5.5 years after treatment 
began [393,396,398]. The longest seizure-free period documented following discontinuation 
of antiepileptic drugs was approximately 11 years [393]. In single cases, a response to 
vigabatrin, carbamazepine, phenobarbital, or valproate and levetiracetam, has been reported 
[387,389,393,394,396,399-404]. The ketogenic diet was used in about 1% of affected 
individuals, with slight or no response [389,405]. Two cases were reported to have had 
surgical treatment of the epilepsy: one became seizure-free following corpus callosotomy 
(Otsuka et al 2010); the other had a significant reduction in seizure frequency following 
resection of focal cortical dysplasia [389]. 
 
ST3GAL3-related epileptic encephalopathy 
The ST3GAL3 gene encodes encodes a sialyltransferase involved in the biosynthesis of sialyl-
Lewis epitopes on cell surface–expressed glycoproteins. These glycoproteins form the 
glycocalyx, composed of sialic acids that act as key determinants of a variety of cellular 
recognition and communication processes [406].	In four members of a consanguineous 
Palestinian family with early infantile epileptic encephalopathy, a homozygous mutation in 
the ST3GAL3 gene was identified. The patients had West syndrome that evolved to Lennox-
Gastaut syndrome with severe intellectual disability. The authors report that only vigabatrin 
was effective (with “rare seizures”) in three of the four cases [407]. 
 
SYNGAP1-related epileptic encephalopathy 
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The SYNGAP1 gene encodes a brain-specific synaptic Ras GTP-ase activating protein that is 
largely localized to dendritic spines in neocortical pyramidal neurons	and	is critical for 
cognition and synapse function [408].	Syngap1 haploinsufficiency disrupts the 
excitatory/inhibitory balance in the developing hippocampus and cortex and results in 
accelerated glutamatergic synapse maturation [409]. SYNGAP-1 mutations are associated 
with a broad phenotypic spectrum, including epileptic encephalopathies, autism and 
intellectual disability [5,7,408,410-412]. A literature overview by von Stülpnagel et al.[411] 
showed that good seizure control was achieved with valproate and topiramate in previously 
reported patients with epilepsy associated with SYNGAP1 mutations, although not all the 
patients had epileptic encephalopathies. A more recent study described 16 unrelated 
individuals with loss-of-function SYNGAP1 mutations and epileptic encephalopathy; the 
epilepsy responded to a single antiepileptic drug, mostly valproate, in seven patients and was 
pharmacoresistant in nine [412]. 
 
TBC1D24-related epileptic encephalopathy  
The TBC1D24 gene encodes a member of the Tre2-Bub2-Cdc16 (TBC) domain-containing 
RAB-specific GTPase-activating proteins, and is involved in regulation of synaptic vesicle 
trafficking and in brain and somatic development [413]. TBC1D24-related epilepsy 
comprises a wide phenotypic spectrum that includes early-infantile epileptic encephalopathy 
[414]. Early-onset progressive myoclonic epilepsy with dystonia and epilepsy of infancy with 
migrating focal seizures have also been reported [415-417]. All cases with early-infantile 
epileptic encephalopathy due to mutations in TBC1D24 described so far were drug-resistant, 
and no specific antiepileptic drugs have emerged as being effective [414]. 
 
TCF4-related epileptic encephalopathy 
TCF4 is a broadly expressed basic helix-loop-helix (bHLH) protein that functions as a 
homodimer or as a heterodimer with other bHLH proteins. Mutations in the TCF4 gene are 
known to cause Pitt-Hopkins syndrome, characterized by an intellectual disability, epilepsy, 
abnormal breathing patterns, short stature, microcephaly, and a specific facial gestalt, 
including deep-set eyes, a broad nasal base and a wide mouth with a tented upper lip [418].	It 
has been suggested that missense mutations are associated with higher seizure frequency 
[419], but a definite genotype-phenotype correlation has not been defined [420]. A recent 
cross-sectional study of 101 individuals with a molecularly-confirmed diagnosis of Pitt-
Hopkins syndrome included 38 cases with epilepsy. Of these, 24 participants were on 
antiepileptic drugs, mostly valproate, levetiracetam, lamitrigine and carbamazepine, or 
combinations of these. There was no specific medication that was more successful in 
decreasing seizures than other medications. Seizures remained drug-resistant in some 
participants, but in most cases antiepileptic treatment was successful, with 23.7% of patients 
who were seizure-free. Lennox-Gastaut syndrome has been mentioned once as the epilepsy 
phenotype [421]. 
 
WWOX-related epileptic encephalopathy 
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The WWOX gene is a putative tumor suppressor, located at the second most fragile site of the 
human genome, known as FRA16D. Mutations of the WWOX gene have been associated with 
tumorigenesis [422]. The expression of WWOX protein in the developing brain and spinal 
cord in the embryo and newborn mice together with histological findings (many vacuoles in 
the hippocampus and amygdala) show a convincing evidence of its role in neural 
development [423]. Early-onset epileptic encephalopathies, including West syndrome, have 
been associated with WWOX mutations [424,425]. Seizures were partially controlled on a 
combination of valproate and lamotrigine in the siblings reported by Abdel-Salam et al.[424].	
Five patients were reported by Mignot et al.[425]: all had pharmacoresistant focal or 
multifocal seizures, with some of them having also experienced generalised seizures. One 
patient had West syndrome.	Seizures ‘partially responded’ to valproate, vigabatrin, high 
doses of hydrocortisone and clobazam in a case diagnosed retrospectively after death [426]. 
Another case with WWOX-related epileptic encephalopathy has been reported to show 
‘partial response’ to antiepileptic medications including phenobarbitone, clobazam and 
topiramate [427]. 
 
Cases with single reports or less clear evidence 
The COL4A1 gene encodes the alpha-1 subunit of collagen type IV. Type IV collagen does 
not form ordered fibrillar structures; rather, a meshwork is formed by four molecules held 
together at the ends. Disorders related to COL4A1 mutations are considered a systemic 
disease, including a broad spectrum of cerebrovascular lesions (porencephaly and transmantle 
lesions, causing hydranencephaly or schizencephaly), and also lesions of the kidneys, eyes, 
heart, and skeletal muscles [428]. Seizures are often reported as part of the clinical spectrum 
of COL4A1 mutation and may not be only secondary to cerebravacular lesions [429]. 
Recently, Hino-Fukuyo et al.[430] reported a child with an epileptic encephalopathy (without 
cerebrovascular lesions on neuroimaging) and carrying a de novo COL4A1 mutation, who 
became seizure-free after	a functional hemispherectomy. 
The ERBB4 gene is a member of the epidermal growth factor receptor (EGFR) family of 
tyrosine kinase receptors and plays a crucial role in numerous neurobiological processes in 
the developing and adult brain [431]. A de novo reciprocal translocation, disrupting the 
ERBB4 gene, was found in a case with early myoclonic encephalopathy, with seizures 
refractory to antiepileptic treatment [432]. Neuregulin 1 (NRG1) is a member of a family of 
neurotrophic factors that acts by activating the tyrosine kinase of ErbB receptors, including 
ErbB4 [433]. Li et al. [434] identified the Kv1.1 subfamily of voltage-gated potassium 
channels as a new molecular target of NRG1-ErbB4 signaling in the regulation of 
interneuronal excitability and revealed that NRG1-ErbB4-Kv1.1 signaling may be involved 
in the pathophysiology of epilepsy, suggesting that ErbB4 might be targeted to attain 
antiseizure effects in the epilepsies broadly. 
The FLNA	gene encodes filamin A, a widely expressed actin-binding protein that regulates 
reorganization of the actin cytoskeleton by interacting with integrins, transmembrane receptor 
complexes, and second messengers. Filamins crosslink actin filaments into orthogonal 
networks in the cytoplasm and participate in the anchoring of membrane proteins to the actin 
cytoskeleton. FLNA mutations can cause X-linked dominant periventricular heterotopia, a 
disorder in which many neurons fail to migrate to the cerebral cortex and persist as nodules 
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lining the ventricular surface. Heterozygous females with the disorder present with epilepsy 
and other signs, including patent ductus arteriosus and coagulopathy, whereas hemizygous 
affected males usually die embryonically [435]. Cases with FLNA mutations and epileptic 
encephalopathies have been reported [5,436]; of these one did not have evidence of cortical 
malformations on neuroimaging [5]. 
The GPHN gene encodes gephyrin, an organizational protein that clusters and localizes the 
inhibitory glycine and GABA receptors to the microtubular matrix of the neuronal 
postsynaptic membrane [437]. A GPHN de novo missense mutation has been reported in a 
patient with epileptic encephalopathy resembling Dravet syndrome. Phenobarbital was 
ineffective, but seizures were eventually controlled by carbamazepine. Every attempt to stop 
or reduce the medication led to seizure recurrence. The missense mutation was shown to 
abolish both postsynaptic clustering with subsequent impairment of GABAergic synapse 
function, and synthesis of the molybdenum cofactor, which is vital for the function of 
molybdo-enzymes, without affecting the structure and folding of the protein [438]. 
The MAGI2 encodes a synaptic scaffolding protein which is essential for development and 
maintenance of synapses, including receptor endocytosis and postendocytotic trafficking. 
MAGI2-dependent endocytosis is also essential for ciliogenesis [439]. Marshall et al.[440] 
described a deletion of the MAGI2 gene in 15 of 16 patients with infantile spasms. However 
more recent studies suggest that MAGI2 mutations are not common causes of infantile 
spasms [5,441,442].  
Hemimegalencephaly is a rare congenital malformation of the brain characterized by 
overgrowth of one hemisphere [443]. It has variable presentation ranging from focal seizures 
to epileptic encephalopathy, hemideficits, and mental retardation. The mechanistic target of 
rapamycin (MTOR) is a highly conserved protein kinase that is found in two structurally and 
functionally distinct protein complexes: TOR complex-1 (TORC1) and TORC2. The mTOR 
signaling cascade regulates processes involved in cell growth and homeostasis in response to 
many metabolic cues. Mutations of MTOR have been associated with a spectrum of brain 
overgrowth phenotypes including hemimegalencephaly [444]. Surgery is usually the 
treatment of choice in hemimegalencephaly [445], however targeted treatment with inhibitors 
of the MTOR pathway may become an alternative option in the future. 
 
The NECAP1 gene encodes an accessory protein involved in clathrin-mediated endocytosis in 
synapses. To date, only one consanguineous Saudi Arabian family, with six members who 
had early infantile epileptic encephalopathy (Ohtahara syndrome), has been reported. All 
affected subjects developed intractable seizures in early infancy [446].		
NEDD4L encodes an E3 ubiquitin ligase that regulates channel internalization and turnover. 
It appears to have roles in regulating various respiratory, cardiovascular, renal, and neuronal 
functions [447]. Only one case of early-onset epileptic encephalopathy due to NEDD4L 
mutation has been reported so far, with onset of infantile spasms at the age of five months. 
The spasms settled by 25 months, but focal seizures continued despite multiple trials of 
treatment [5]. 
The gene NRXN1 encodes neurexin 1, one of the cell-surface receptors that bind neuroligins 
to form a calcium-dependent neurexin/neuroligin complex at synapses in the central nervous 
system. This trans-synaptic complex is required for efficient neurotransmission and is 
involved in the formation of synaptic contacts [448]. Cases of epileptic encephalopathy 
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associated with NRXN1 mutations have been reported, although the epilepsy phenotype is not 
well characterised yet [449,450]. 
 
Conclusions 
Growth in gene discovery has radically changed our understanding of epileptic 
encephalopathies. As more and more genes have been associated with various electroclinical 
syndromes, such as West syndrome, Dravet syndrome, Ohtahara syndrome, and others, it will 
hopefully become possible to move towards treatment focused on the underlying genetic 
aetiology and resultant pathophysiology. The picture is certainly complex, with genotypic 
and phenotypic heterogeneity, and is compounded by a degree of lack of detail, often 
inevitable in retrospective case reports, in specification of the drug response in many 
published reports. Also, we note that classification of the epilepsy syndromes was variable, 
and not always specified in the original references. Aspects of phenotypic classification are  
beyond the scope of this review, and we specifically did not attempt to re-interpret or 
interpolate phenotypes. We therefore described epilepsy and seizure types as reported in the 
original articles, without attempting to re-classify epilepsy syndromes. Treatment remains 
challenging	in most cases, but the available evidence may provide some guidance for 
treatment: for example, ACTH seems to be effective in controlling infantile spasms in a 
number of genetic epileptic encephalopathies, irrespective of the actual genetic cause, raising 
some questions about the precision medicine concept. This may be a biased view as ACTH is 
one of the few agents employed in the treatment of infantile spasms – more research is 
needed. 
Understanding the effect of the mutation is probably crucial for targeted treatment. In 
epileptic encephalopathies, there is a broad range of disease mechanisms including 
channelopathies, synaptic dysfunction, transporter defects, transcriptional dysregulation, 
impaired DNA repair and chromatin remodeling and metabolic defects. Moreover, in many 
cases the underlying neurobiological complexity cannot be entirely defined [2]. For this 
reason, we are still far from systematic application of targeted treatments in epilepsy. 
Furthermore, it is important to note that in many epileptic encephalopathies non-
pharmacological interventions may also prove helpful; these may include physical 
management, monitoring, and prevention of secondary complications (e.g. for Dravet 
Syndrome; [263,451]). Co-morbidities are often present and need to be taken in account 
when pharmacological treatment is chosen. Dysfunctional genetic pathways can indeed affect 
multiple organs and treatment should therefore be considered for the entire phenotype. 
A systems-level approach based on gene co-expression network analysis has suggested 
functional disruption of a co-expression network of 320 genes, via gene mutation or altered 
expression, as a convergent mechanism regulating susceptibility to epilepsy broadly. 
Valproate was predicted to preferentially restore the downregulation of the network in 
epilepsy toward health [452]. As showed in this review, valproate is not effective in many 
epileptic encephalopathies. However, systems biology may expand the application of targeted 
treatments in epilepsy. 
Gene therapy represents a further potentially promising treatment for drug-resistant epilepsy, 
but there are still several challenges to face, including the validation of experimental models 
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of human pharmacoresistant epilepsy, establishment of sensitive and specific measures of 
therapeutic efficacy, and evaluation of the long-term safety [453]. There is, however, 
accumulating evidence that treating severe epilepsies based on the genetic aetiology could 
dramatically transform clinical care and prognosis. 
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